Drug Profile
Research programme: apolipoprotein E-targeted Alzheimer's disease therapeutics - Madera Biosciences
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Madera BioSciences
- Class Small molecules
- Mechanism of Action Apolipoprotein E modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 25 Aug 2011 Preclinical trials in Alzheimer's disease in USA (unspecified route)